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• ABCB1 C1236T (rs1128503) was marginally associated with improved overall survival in 4,616 invasive ovarian cancer patients regardless of chemotherapy.
• Analysis of an additional 1,562 SNPs flanking ABCB1 in ~3000 invasive ovarian cancer patients yielded no new signals.
• Analysis of ABCB1 expression in 143 ovarian tumors showed that ABCB1 expression may worsen prognosis in sub-optimally debulked patients.a b s t r a c ta r t i c l e i n f oArticle history:
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Objective. ABCB1 encodes the multi-drug efflux pump P-glycoprotein (P-gp) and has been implicated in
multi-drug resistance.We comprehensively evaluated this gene and flanking regions for an associationwith clin-
ical outcome in epithelial ovarian cancer (EOC).
Methods. The best candidates from fine-mapping analysis of 21 ABCB1 SNPs tagging C1236T (rs1128503),
G2677T/A (rs2032582), and C3435T (rs1045642) were analysed in 4616 European invasive EOC patients from
thirteenOvarian Cancer Association Consortium(OCAC) studies and TheCancerGenomeAtlas (TCGA). Additionally
we analysed 1,562 imputed SNPs around ABCB1 in patients receiving cytoreductive surgery and either ‘standard’
first-line paclitaxel–carboplatin chemotherapy (n = 1158) or any first-line chemotherapy regimen (n = 2867).
We also evaluated ABCB1 expression in primary tumours from 143 EOC patients.
Result. Fine-mapping revealed that rs1128503, rs2032582, and rs1045642were the best candidates in optimally
debulked patients. However, we observed no significant association between any SNP and either progression-free
survival or overall survival in analysis of data from14 studies. Therewas amarginal association between rs1128503
and overall survival in patients with nil residual disease (HR 0.88, 95% CI 0.77–1.01; p = 0.07). In contrast, ABCB1
expression in the primary tumour may confer worse prognosis in patients with sub-optimally debulked tumours.
Conclusion. Our study represents the largest analysis of ABCB1 SNPs and EOC progression and survival
to date, but has not identified additional signals, or validated reported associations with progression-free
survival for rs1128503, rs2032582, and rs1045642. However, we cannot rule out the possibility of a subtle
effect of rs1128503, or other SNPs linked to it, on overall survival.© 2013 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Over the past three decades, significant advances have beenmade in
chemotherapy for ovarian cancer, and the combination of cytoreductive
surgery followed by the doublet of a taxane (paclitaxel 135–175 mg/m2)
and carboplatin (AUC N 5), has been the most common regimen for pri-
mary treatment of this disease [1]. However, resistance to chemotherapy
remains a major challenge to treatment, and although multidrug resis-
tance (MDR) has beenwidely studied in in vitromodels, the translational
utility of this research remains elusive. The identification and analysis
of genes relevant to MDR in patients may contribute to a better under-
standing of this phenomenon and potentially help circumvent this
obstacle.
ABCB1, the most extensively studied ATP-binding cassette (ABC)
transporter, encodes the multi-drug efflux pump P-glycoprotein (P-gp)
and is involved in the transport of a wide range of anti-cancer drugs in-
cluding paclitaxel [2,3]. ABCB1, located at 7q21.12, is genetically very var-
iable, and it is likely that single nucleotide polymorphisms (SNPs) in this
genemay have significant effects on the expression and function of P-gp,
and hence the absorption, metabolism and clearance of P-gp substrates.
Of particular interest has been the nonsynonymous variant G2677T/A
(rs2032582) which results in an amino acid change at codon 893
(Ala893Ser/Thr) in exon 21 and forms part of a common haplotype
that includes two synonymous SNPs, C1236T (rs1128503) in exon
12 and C3435T (rs1045642) in exon 26. Studies evaluating allelic
or haplotypic effects of these three SNPs onmRNAor protein expression
in a wide range of human tissues have been extensively reviewed and
found to be inconclusive [4,5]. Likewise, association studies of ABCB1
polymorphisms in EOC cases receiving taxane-based chemotherapy
regimens have to date produced conflicting and inconclusive results
[6–11].
We evaluated ABCB1 SNPs and EOC disease progression and survival
among 4,616 women participating in thirteen studies from the Ovarian
Cancer Association Consortium (OCAC) [12] and The Cancer Genome
Atlas (TCGA) (http://cancergenome.nih.gov/). We first queried the
SNP(s) that could account for our reported association betweenrs2032582 and rs1128503 and outcome in the AOCS study [10,11]
by fine-mapping the ABCB1 locus in optimally debulked AOCS patients
receiving standard first-line paclitaxel–carboplatin chemotherapy. We
then analysed the best SNPs in a much larger cohort of patients with
more mature clinical follow-up data from the OCAC and TCGA, and
evaluated an additional 1,562 SNPs on chromosome 7 flanking ABCB1.
Methods
Study subjects and ethics statement
EOC patients were from thirteen OCAC studies, and TCGA. European
ancestry was determined using the program LAMP [13] to assign inter-
continental ancestry based on the HapMap (release no. 22) genotype
frequency data for European, or assumed to be of European ancestry
based on self-report or geographic location where genetic markers were
unavailable. Clinical definitions and criteria for progression across studies
have been previously described [14]. All studies received approval from
their respective human research ethics committees, and all OCAC partici-
pants provided written informed consent. Details of TCGA can be found
at http://cancergenome.nih.gov/.
DNA extraction, genotyping, and imputation
DNA extraction, genotyping methods and quality assurance for all
samples have been previously described [11]. Data for TCGA patients
was downloaded through the TCGA data portal and assessed for ances-
tral outliers to determine those of Europeandescent. Imputation of SNPs
at the chromosome 7 locus was performed usingminimac [15] following
pre-phasing by MACH algorithm 1.0 [16] utilizing information from 70
ABCB1 SNPs genotyped in all European ovarian cancer patients on the
Illumina Infinium iSelect array designed by the Collaborative Oncological
Gene-environment Study (iCOGS) [17]. Genotypes were imputed to the
European subset of the phased chromosomes from the 1000 Genome
project (version 3). Genotyping methods and quality assurance of OCAC
samples included on the iCOGs platform have been previously reported
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sequence extending out to the first recombination peaks with a recombi-
nation rate greater than 40, and spanning 85,570,519 bp–88,736,135 bp
of chromosome 7 (NCBI build 37). We evaluated only those with
minor allele frequency (MAF) N0.05 and reasonable imputation quality
(imputed r2 N 0.3).
SNP selection and fine mapping
We used the Tagger program within Haploview [18] to select 18
ABCB1 tagging SNPs (Hapmap Phase II release #24) within a 60 kb re-
gion encompassing rs2032582, and genotyped these and our three pre-
viously reported SNPs (rs1128503, rs2032582, and rs1045642) [10,11]
in optimally debulked AOCS patients that met our inclusion criteria
(n = 433). SNPs were analysed both independently and in forward
and backward log-additive stepwise Cox proportional hazards (PH)
models adjusted for tumor stage and level of residual disease, using a
conservative p-value of 0.05 to enter or exit the model [19]. We also in-
vestigated haplotype frequencies for all patients genotyped for these 21
SNPs (n = 615) using the Beagle Genetic Analysis Software package
v.3.3.2 for inferring haplotype phase or sporadic missing genotype
data in unrelated individuals [20]. The likelihood ratio test was used
to compare regression models of the three most common ABCB1 haplo-
types (alternate models) versus the rs2032582 (null model) to test the
likelihood that any observed association was due to haplotype effects.
ABCB1 expression analysis
RNA was prepared from 143 AOCS serous ovarian tumors obtained
at surgery prior to chemotherapy using the QIAGEN RNeasy extraction
kit (QIAGEN, Australia) and reverse transcribed as previously described
[21]. Quantification of expression utilising TaqMan® assays [ABCB1 (ID
Hs00184500_m1), GUSB (ID 4326320E), HPRT (ID 4326321E) and PGK1
(ID 4326318E)] were conducted in duplicate using a 7900HT Fast
Real-Time PCR system. Relative expression was calculated by the
(delta–delta) Ct method using RQ Manager (Applied Biosystems) as the
geometric mean of the expression values against three control genes
[22]. Values were log transformed and ABCB1 expression was analysed
as a continuous variable using Cox regression. Expression values
for significant associations were dichotomised into low vs. high for
Kaplan-Meier analysis. We also analysed 374 TCGA serous EOC cases
using publicly available data (http://tcga-data.nci.nih.gov/) [23].
Statistical analysis
Progression-free survival (PFS) was defined as the interval between
the date of histological diagnosis and the first confirmed sign of disease
progression or death, as previously described [14]. Overall survival (OS)
was the interval between the date of histological diagnosis and death
from any cause. To control for ascertainment bias, prevalent cases,
defined as having an interval N12 months between the date of histolog-
ical diagnosis and DNA collection, were excluded from the analysis.
Analysis of PFS and OS was restricted to European/non-Hispanic
white invasive EOC patients of all histologies classified as ‘standard’ if
they had ≥4 cycles of paclitaxel and carboplatin intravenously (IV) at
3-weekly intervals, or ‘all chemo’ if they had any chemotherapy regimen
following cytoreductive surgery; the majority of women in the ‘standard’
cohort were known to have had paclitaxel at 175 or 135 mg/m2 and
carboplatin AUC 5 or 6. Patients included in our previous report [11]
were not excluded from the current analysis because patient outcome
and treatment data has since been updated. To maximize the statistical
power for analysis of the best fine-mapping SNPs in OCAC and TCGA
studies, we combined caseswith actual andwell-imputed (r2 N0.9) geno-
types where available.
Cox PH models were used to estimate the hazard ratios (HRs) and
95% confidence intervals (CIs) for PFS and OS associated with ABCB1SNPs in EOC patients classified as ‘standard’ and ‘all chemo’ for first-
line chemotherapy. We evaluated potential confounders of PFS and
observed a highly significant association between PFS and residual
disease, tumor stage, histology and grade (log-rank p b 0.0001; data
not shown) and therefore included these covariates in all regression
models. Additionally, OS analysis was adjusted for age at diagnosis.
SNPs were modelled assuming log-additive effects by fitting the
number or dosage score (imputed data) of rare alleles carried as a
continuous covariate, and stratified by study.Weobserved a statistically
significant interaction between the rs2032582 genotype and residual
disease (p = 0.001) and analysed SNPs for nil residual disease sepa-
rately, as well as optimally (≤1 cm residual disease) and sub-
optimally debulked (N1 cm residual disease) patients. Between-study
heterogeneity was assessed using the likelihood ratio test to compare
regression models with and without a genotype-by-study interaction
term. The median follow-up of the analysis cohort was estimated
using the reverse Kaplan–Meier method [24]. All tests for association
were two-tailed. The significance threshold for the fine-mapping
study was p b 0.05. However, a threshold of p b 10−3 was used for
the best fine-mapping candidate SNPs evaluated in the larger EOC co-
hort because we explored sixteen independent hypotheses according
to chemotherapy regimen and debulking status. For the 1,562 imputed
SNPswe used amodified Bonferroni adjustment that takes into account
linkage disequilibrium (LD) between SNPs [25,26], yielding a signifi-
cance threshold of 4.6 × 10−4 required to keep the Type I error rate at
5%. All analyses were performed in STATA SE v. 11 (Stata Corp., USA),
SPSS, and the R project for Statistical Computing v2.14 (http://www.r-
project.org/).Results
Details of study design, case ascertainment, and clinical characteris-
tics of all women from participating OCAC studies have been described
elsewhere [27,28] and are summarized in Tables S1 and S2. A total of
4942 European/non-Hispanic White women with invasive EOC and
detailed clinical and treatment data were eligible for inclusion in the
analysis. The median follow-up of the analysis cohort was 5.9 (95% CI
5.7–6.0) years. All genotype data included in this analysis conformed
to quality assurance criteria for inclusion.
Progression-free survival (PFS) estimates from18ABCB1 tagging SNPs
selected for preliminary fine-mapping, and the three coding SNPs
(rs1128503, rs2032582, and rs1045642) analysed in a subset of patients
with optimal debulking from the AOCS (residual disease ≤ 1 cm, n =
433) are shown in Table 1. Nine SNPs that were significantly associated
with PFS (p b 0.05) in adjusted single-SNP analyses were then analysed
by stepwise regression. Only rs2032582 remained significantly asso-
ciated with PFS in forward stepwise modelling (p = 0.03). Likewise, in
the backward stepwise procedure, the sequential removal of each
of the other eight SNPs successively improved the significance level
of rs2032582 to that of the single SNP. The most informative model
included one other SNP, rs4148738 (p = 0.086) which is perfectly
correlated with rs2032582 in the1000 Genomes reference population.
We therefore concluded that rs2032582 best explains the observed
association with PFS in this sample.
Haplotypes estimated for 1230 chromosomes in the 615 women
with genotype data for the 21 SNPs revealed that the most common
haplotypes contained the minor alleles of rs1128503, rs2032582, and
rs1045642 (Table S3). Likelihood ratio tests comparing regression
models in optimally debulked carriers of the three most common
haplotypes vs. carriers of the minor allele of rs2032582 only, showed
no significant improvement in PFS estimates attributable to haplo-
types (likelihood ratio p = 0.8). We further expanded analysis of
the rs1128503–rs2032582–rs1045642 haplotype to 3437 invasive
EOC cases fromOCACwith genotype data and observed a similar distri-
bution of haplotypes as seen in the preliminaryfinemapping exercise of
Table 1
Independent SNP effects on progression-free survival in ABCB1 tagging SNPs selected for fine-mapping in optimally debulked AOCS cases (n = 433).
Unadjusted aAdjusted
SNP Gene location LD block bChr position HR 95% CI P HR 95% CI P
rs7793196 Intergenic 1 86767498 1.06 (0.84–1.34) 0.619 1.09 (0.86–1.37) 0.47
rs6946119 3′ Flank 1 86773516 1.22 (0.99–1.51) 0.064 1.15 (0.94–1.42) 0.175
rs6979885 Intronic 2 86782112 1.35 (1.09–1.68) 0.007 1.26 (1.02–1.56) 0.033
rs2235048 Intronic 2 86783162 1.32 (1.09–1.61) 0.004 1.26 (1.05–1.52) 0.015
rs1045642 Exonic (sSNP) 86783296 1.34 (1.10–1.62) 0.003 1.25 (1.03–1.51) 0.022
rs2032582 Exonic (nsSNP) 3 86805269 0.74 (0.61–0.88) 0.001 0.74 (0.62–0.89) 0.001
rs4148738 Intronic 3 86807700 0.76 (0.63–0.92) 0.006 0.79 (0.65–0.96) 0.015
rs10276603 Intronic 3 86816178 1.01 (0.77–1.34) 0.919 1.07 (0.81–1.41) 0.642
rs2091766 Intronic 3 86819155 1.23 (1.00–1.50) 0.045 1.12 (0.91–1.38) 0.272
rs1128503 Exonic (sSNP) 86824252 0.8 (0.66–0.97) 0.022 0.85 (0.70–1.04) 0.119
rs12704364 Intronic 3 86825826 1.24 (1.01–1.51) 0.035 1.17 (0.96–1.42) 0.13
rs956825 Intronic 3 86836926 1.11 (0.91–1.36) 0.292 1.04 (0.85–1.28) 0.686
rs10260862 Intronic 4 86846133 1.14 (0.90–1.45) 0.271 1.15 (0.91–1.46) 0.23
rs10264990 Intronic Singleton 86847266 1.4 (1.13–1.74) 0.002 1.33 (1.07–1.65) 0.01
rs1202174 Intronic 5 86854023 1.17 (0.96–1.43) 0.12 1.19 (0.97–1.45) 0.096
rs17327442 Intronic 5 86857641 1.22 (0.91–1.62) 0.186 1.15 (0.86–1.55) 0.345
rs1202184 Intronic 5 86858552 1.25 (1.03–1.52) 0.025 1.24 (1.02–1.51) 0.03
rs1211152 Intronic 5 86859765 1.31 (0.87–1.97) 0.195 1.3 (0.86–1.96) 0.21
rs17327624 Intronic Singleton 86861468 1.01 (0.79–1.30) 0.925 0.98 (0.76–1.26) 0.871
rs2188526 Intronic 6 86865213 0.8 (0.65–0.97) 0.022 0.77 (0.63–0.94) 0.009
rs13233308 Intronic Singleton 86889611 0.81 (0.67–0.98) 0.028 0.78 (0.64–0.94) 0.01
a: Adjusted estimates adjusted for stage and level of residual disease.
b: Chromosomal position and order for haplotype analysis (from HapMap Phase II (release #24).
Table 2
Estimates for three ABCB1 coding SNPs in invasive ovarian cancer cases according to treatment group and debulking status.
SNP aAnalysis subset bN % Relapsed % Died cProgression-free survival c,dOverall Survival
HR 95% CI P HR 95% CI P
G2677TA (rs2032582) All cases
Standard 1882 70.14 51.91 0.99 (0.91–1.08) 0.83 1.00 (0.90–1.10) 0.92
All chemo 4450 67.30 52.09 1.02 (0.96–1.07) 0.55 1.00 (0.94–1.07) 0.93
Nil residual disease
Standard 687 48.18 31.15 1.03 (0.87–1.22) 0.75 1.00 (0.81–1.23) 0.99
All chemo 1665 43.96 30.27 0.95 (0.85–1.06) 0.37 0.89 (0.77–1.01) 0.08
Optimally debulked (≤1 cm)
Standard 1118 61.72 46.15 1.00 (0.90–1.12) 0.97 0.97 (0.85–1.10) 0.61
All chemo 2600 56.96 43.88 0.98 (0.91–1.06) 0.68 0.95 (0.87–1.03) 0.21
Sub–optimally debulked (N1 cm)
Standard 672 84.52 60.86 1.01 (0.89–1.15) 0.84 1.05 (0.91–1.22) 0.49
All chemo 1654 83.68 64.81 1.05 (0.97–1.14) 0.22 1.05 (0.96–1.15) 0.24
C1236T (rs1128503) All cases
Standard 1873 70.10 51.79 1.02 (0.94–1.11) 0.57 0.98 (0.89–1.08) 0.75
All chemo 4436 67.22 51.98 1.04 (0.98–1.10) 0.19 1.00 (0.94–1.07) 0.97
Nil residual disease
Standard 681 48.02 30.84 1.07 (0.90–1.26) 0.46 0.95 (0.77–1.17) 0.63
All chemo 1659 43.88 30.14 1.00 (0.89–1.11) 0.96 0.88 (0.77–1.01) 0.07
Optimally debulked (≤1 cm)
Standard 1110 61.62 46.04 1.04 (0.93–1.16) 0.50 0.94 (0.83–1.07) 0.35
All chemo 2592 56.87 43.79 1.01 (0.94–1.09) 0.76 0.95 (0.87–1.03) 0.20
Sub-optimally debulked (N1 cm)
Standard 671 84.50 60.66 1.05 (0.92–1.19) 0.49 1.08 (0.93–1.26) 0.29
All chemo 1648 83.62 64.68 1.07 (0.98–1.15) 0.12 1.06 (0.97–1.16) 0.23
C3435T (rs1045642) All cases
Standard 1873 70.10 51.79 0.99 (0.91–1.07) 0.81 0.97 (0.88–1.06) 0.51
All chemo 4435 67.24 51.97 0.99 (0.94–1.04) 0.64 1.00 (0.94–1.06) 0.99
Nil residual disease
Standard 681 48.02 30.84 0.94 (0.80–1.11) 0.49 0.92 (0.74–1.14) 0.44
All chemo 1658 43.91 30.10 1.00 (0.89–1.11) 0.98 1.06 (0.93–1.22) 0.37
Optimally debulked (≤1 cm)
Standard 1110 61.62 46.04 0.98 (0.88–1.09) 0.68 0.98 (0.87–1.11) 0.77
All chemo 2591 56.89 43.77 0.98 (0.91–1.05) 0.51 1.01 (0.93–1.10) 0.77
Sub-optimally debulked (N1 cm)
Standard 671 84.50 60.66 0.98 (0.87–1.11) 0.77 0.93 (0.80–1.08) 0.33
All chemo 1648 83.62 64.68 1.00 (0.93–1.08) 0.99 1.00 (0.91–1.09) 0.95
a ‘Standard’ refers to cases receiving cytoreductive surgery and≥4 cycles of paclitaxel and carboplatin; ‘All chemo’ refers to cases receiving cytoreductive surgery and any chemotherapy
regimen.
b N includes BAV cases which were included in OS analysis only.
c All estimates are stratified by study and adjusted for histology (serous, mucinous, endometrioid, clear cell and other epithelial), tumor stage (I to IV), residual disease (nil vs. any), and
grade (low vs. high for all except MAY & MAC studies which was analysed as a 4-levels variable).
d OS estimates are additionally adjusted for age at diagnosis.
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Fig. 1. Forest plot of study-specific estimates for rs1128503 and overall survival for
patients with nil residual disease receiving any chemotherapy regimen Estimates for
HAW and NCOmissing due to insufficient data for this subgroup.
12 S.E. Johnatty et al. / Gynecologic Oncology 131 (2013) 8–14AOCS cases only. No significant haplotype effects were observed in any
subset of cases in analysis of PFS (Table S4).
Based on our fine-mapping and haplotype analysis, as well as a re-
cent report that rs1045642 and rs1128503 may indeed be functionally
relevant though silent [29], we evaluated the rs1128503, rs2032582,
and rs1045642 SNPs in the largest available dataset of 4,461 European
invasive EOC patients with actual (≥80%) and well-imputed genotypes
(imputation r2 N 0.9) for these three SNPs.We observed only amarginal
inverse association between the rare allele of rs1128503 and OS in
patients with nil residual disease treated with any chemotherapy (HR
0.88, 95% CI 0.77–1.01; p = 0.07) (Table 2 & Fig. 1). A similar effect
was observed for rs2032582 (p = 0.08; r2 = 0.9 with rs1128503).
We observed no significant association between any of the three SNPs
and either PFS or OS in invasive EOC or any other subset for residual
disease or treatment groups (Table 2). Additionally, we explored the
dominant model and found no evidence to support dominant effects
for these SNPs (data not shown). There was no evidence of between-
study heterogeneity for any of these three SNPs (p ≥ 0.2).
Finally, 1,562 of the 2,745 imputed chromosome 7 SNPs with MAF
N0.05 and imputation r2 N 0.3 were analysed in ~3,000 European inva-
sive EOC patients but no evidence of an associationwith PFS or OS at the
pre-specified threshold of p b 4.6 × 10−4 was observed in any of the
chemotherapy subsets (Tables S5–S8).Fig. 2. Kaplan–Meier survival analysis of ABCB1 gene expression in serous ovarian cancer. In th
overall cohort, or (B) in the subgroup of patients with sub-optimally debulked tumors. Kapla
low expression with respect to the optimal cut-point, determined as the 15th percentile in th
were calculated according to the log-rank test.ABCB1mRNAexpression levels in 143AOCS serous tumors indicated
that high-level ABCB1 expression was associated with shorter PFS both
overall (p = 0.003) and in sub-optimally debulked patients (p = 0.02;
Fig. 2), although the effect diminished upon adjustment for residual dis-
ease status and tumor stage (Table 3). The mean expression of ABCB1
was higher in sub-optimally debulked patients compared to optimally
debulked (1.48 ± 0.1 vs 2.74 ± 0.79, p = 0.04) suggesting a possible
link between ABCB1 and disease progression in patients unable to be
optimally debulked. In the TCGA dataset, a trend for shorter OS was
observed in sub-optimally debulked patients, which was substantially
strengthened if patients were uniformly treated with regard to pacli-
taxel (Table 3).
Discussion
We have comprehensively analysed the largest study to date of
ABCB1 SNPs and clinical outcome among women with invasive EOC
treated with paclitaxel-based chemotherapy. Fine-mapping analysis
suggested that rs2032582 and the two silent SNPs (rs1128503 and
rs1045642) were indeed the best candidates [29,30]. However analysis
of these SNPs in 4,616 European/non-Hispanic White invasive EOC
patients from theOCAC studies and TCGA showed only amarginal asso-
ciation between rs1128503 (pair-wise r2 with rs2032582 = 0.9) and
overall survival in patients with nil residual disease treated with any
first-line chemotherapy regimen (Table 2 & Fig. 1). Although this asso-
ciation did not meet the threshold for multiple testing, we cannot rule
out a small effect of this SNP or another linked to it on overall survival.
It is likely that this SNP is modifying the effect of residual disease, a sig-
nificant predictor of outcome, on overall survival independently of
chemotherapy regimen, and warrants further investigation. There was
no convincing evidence of an association between PFS or OS and any
of the 1562 SNPs analysed in either the ‘standard’ or ‘all chemo’ subsets
(Tables S5–S8).
A recent systematic literature review of predictive and prognostic
studies of ovarian cancer genetic markers including ABCB1 highlighted
the non-uniformity of outcome definitions and treatment approaches
that limit interpretation and clinical utility, and the need for adequately
powered, well-designed observational studies that might help to re-
solve the present heterogeneity of findings among pharmacogenetic
studies [31]. Our patient data was subjected to stringent quality assur-
ance measures with regard to chemotherapy data in an effort to avoid
disparities in treatment exposure. Chemotherapy data for each studye AOCS cohort, high expression of ABCB1 is associated with shorter PFS, either (A) in the
n–Meier curves were generated following dichotomisation of gene expression to high or
e whole cohort, or the 30th percentile in the sub-optimally debulked subgroup. P-values
Table 3
Analysis of ABCB1 expression in serous EOC tumors.
Cohort N % Relapsed % Died HR Progression-free survival Overall Survival
95% CI P HR 95% CI P
AOCS
Univariate
ABCB1 expressiona 143 81.1 56.6 1.32 (1.03–1.70) 0.028 1.20 (0.92–1.55) 0.173
Multivariate model
ABCB1 expressiona 143 81.1 56.6 1.26 (0.99–1.62) 0.062 1.09 (0.85–1.4) 0.50
Residual disease N1 cm 2.00 (1.36–2.95) b0.001 1.95 (1.24–3.07) 0.004
FIGO Stageb 4.61 (1.84–11.49) 0.001 10.53 (1.45–76.9) 0.02
TCGA sub-optimally debulked patients (N1 cm)
All chemo 91 69.2 58.2 1.24 (0.78–1.97) 0.36 1.58 (0.98–2.57) 0.06
Standard 41 95.1 61 1.83 (0.96–3.49) 0.066 3.39 (1.51–7.62) 0.003
a Normalised expression was analysed as a continuous variable.
b FIGO stage was categorised as favorable (figo stages I & II) or unfavorable (figo stages III & IV).
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by data extractors who were blinded to our study hypothesis. Cases
were included in the ‘standard’ chemotherapy subset if sufficient details
of first-line chemotherapy confirmed that they had in fact received
carboplatin and paclitaxel. Approximately 71% of women in this subset
received a minimum of four cycles of paclitaxel at 175 or 135 mg/m2
and carboplatin AUC 5 or 6. The other 29% in this subgroup were pre-
sumed to have received ≥4 cycles of paclitaxel and carboplatin at these
doses based on patient data that suggested that this was the planned
treatment approach, with due consideration to toxicity data and other
variables that might indicate that the doses or cycles of chemotherapy
actually received were not as planned. Cases known to have received
b4 cycles of paclitaxel and carboplatin due to dose reduction or toxicity
were included only in the ‘all chemo’ analyses. Analysis of the ‘all
chemo’ dataset was designed to test whether any observed SNP associa-
tions from the ‘standard’ subsets would be diminished if indeed such as-
sociations were directly linked to exposure to a P-gp substrate.
To circumvent methodological flaws we restricted the analysis to
European invasive EOC cases participating in the OCAC with standard-
ized definitions of clinical and pathological characteristics. All analyses
were stratified by study to account for unknown sources of variation,
although baseline PFS by OCAC study has previously been shown to be
comparable [14]. The median follow-up of the entire cohort of 4,942
eligible cases was 5.9 (95% CI 5.7–6.0) years. Given the prognosis of
invasive ovarian cancer, it is highly likely that deaths in this cohort
were due to ovarian cancer, and therefore represents a reasonable esti-
mate of the association between SNPs and disease-specific survival.
Despite our rigorous approach to data quality and our null findings,
we cannot rule out the possibility that some polymorphisms around the
ABCB1 locusmay have a very subtle effect on outcomes. Expression stud-
ies suggest that variation in P-gp function is a putative mechanism for
MDR in a wide range of disease [4] and may at least in part contribute
to paclitaxel-based chemotherapy outcomes. It is possible that there
are long range eQTLs that influence the expression of P-gp that were
not genotyped in our fine mapping study of ABCB1. In terms of tumor-
intrinsic ABCB1 function, whilst high levels of ABCB1 can clearly confer
taxane resistance to cancer cells in vitro, the outcomes of numerous stud-
ies examining a potential clinical role are diverse and inconclusive. The
current study suggests that ABCB1 expression in primary tumors may
influence the time to relapse, particularly in the subgroup of patients
with significant residual tumor post-surgery. The relationship between
ABCB1 SNPs and expression has been intensively studied and sometimes
weak associations have been observed between the T allele of rs1045642
and expression in cancer cells [4]. In the relatively large dataset of com-
bined TCGA and AOCS patients (n = 536), we found no association be-
tween the three coding SNPs, rs1045642, rs1128503 and rs2032582
and ABCB1 expression levels (Table S9).There remains a great need to implement high-quality pharma-
cogenomic studies in EOC because the causes of differential treatment
outcomes remain unknown. Promising new biological entities are being
tested for concurrent administrationwith paclitaxel-based treatment reg-
imens [32] which require prolonged administration, and the identifica-
tion of genetic markers may enhance the clinical approaches and cost-
effectiveness of these treatment approaches. However, large clinical trials
or well-designed prospective cohort studies that take into account differ-
ential responses according to EOC tumor types are required to succeed in
defining the role of genetics in treatment response.
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